
Stefan Vegter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12163056/publications.pdf Version: 2024-02-01



STEEAN VECTED

#	Article	IF	CITATIONS
1	Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature. PLoS ONE, 2016, 11, e0146262.	2.5	94
2	Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis. Health Economics Review, 2015, 5, 49.	2.0	4
3	A Network Meta-Analysis of the Relative Efficacy of Treatments for Actinic Keratosis of the Face or Scalp in Europe. PLoS ONE, 2014, 9, e96829.	2.5	103
4	Medication Monitoring and Optimization: A Targeted Pharmacist Program for Effective and Cost-Effective Improvement of Chronic Therapy Adherence. Journal of Managed Care Pharmacy, 2014, 20, 786-792.	2.2	42
5	Improving Adherence to Lipid-Lowering Therapy in a Community Pharmacy Intervention Program: A Cost-Effectiveness Analysis. Journal of Managed Care Pharmacy, 2014, 20, 722-732.	2.2	22
6	Clinical and economic impact of non-adherence in COPD: A systematic review. Respiratory Medicine, 2014, 108, 103-113.	2.9	176
7	Impact of multiple-dose versus single-dose inhaler devices on COPD patients' persistence with long-acting β2-agonists: a dispensing database analysis. Npj Primary Care Respiratory Medicine, 2014, 24, 14069.	2.6	16
8	The Effects of Antitussive Treatment of ACE Inhibitor-Induced Cough on Therapy Compliance: A Prescription Sequence Symmetry Analysis. Drug Safety, 2013, 36, 435-439.	3.2	22
9	Inhaled Corticosteroids and the Occurrence of Oral Candidiasis: A Prescription Sequence Symmetry Analysis. Drug Safety, 2013, 36, 231-236.	3.2	61
10	Persistence with osteoporosis medication among newly-treated osteoporotic patients. Journal of Bone and Mineral Metabolism, 2013, 31, 562-570.	2.7	46
11	Proactive Pharmaceutical Care Interventions Improve Patients' Adherence to Lipid-Lowering Medication. Annals of Pharmacotherapy, 2013, 47, 1448-1456.	1.9	32
12	Sodium Intake, ACE Inhibition, and Progression to ESRD. Journal of the American Society of Nephrology: JASN, 2012, 23, 165-173.	6.1	275
13	Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Dialysis Patients: A Canadian Payer Perspective. Clinical Therapeutics, 2012, 34, 1531-1543.	2.5	12
14	Health technology assessments in personalized medicine: illustrations for cost–effectiveness analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 367-369.	1.4	18
15	Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Chronic Kidney Disease Before and During Dialysis. Value in Health, 2011, 14, 852-858.	0.3	17
16	Using a genetic, observational study as a strategy to estimate the potential cost-effectiveness of pharmacological CCR5 blockade in dialysis patients. Pharmacogenetics and Genomics, 2011, 21, 417-425.	1.5	7
17	Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. American Journal of Managed Care, 2011, 17, 609-16.	1.1	22
18	Review of regulatory recommendations for orphan drug submissions in the netherlands and scotland: focus on the underlying pharmacoeconomic evaluations. Clinical Therapeutics, 2010, 32, 1651-1661.	2.5	28

STEFAN VEGTER

#	Article	IF	CITATIONS
19	Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature. Drug Development Research, 2010, 71, 492-501.	2.9	24
20	Misdiagnosis and mistreatment of a common sideâ€effect – angiotensinâ€converting enzyme inhibitorâ€induced cough. British Journal of Clinical Pharmacology, 2010, 69, 200-203.	2.4	45
21	Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. Pharmacogenetics and Genomics, 2009, 19, 695-703.	1.5	19
22	Replacing hormone therapy-is the decline in prescribing sustained, and are nonhormonal drugs substituted?. Menopause, 2009, 16, 329-335.	2.0	7
23	Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes. Pharmacoeconomics, 2008, 26, 569-587.	3.3	75